Kuvatris Therapeutics, Inc. (formerly PaxMedica) reports a much smaller net loss but severe financial strain for the quarter ended September 30, 2024. The company posted a net loss of $0.9 million for the quarter and $7.6 million for the nine months, compared with losses of $5.0 million and $12.4 million in the prior-year periods, mainly because general and administrative and research and development expenses were sharply reduced.
Cash fell to $444,855 from $4.7 million at December 31, 2023, leaving total assets of $0.8 million against liabilities of $2.8 million and a stockholders’ deficit of $(1.9) million. The filing states there is substantial doubt about the company’s ability to continue as a going concern.
Subsequent events radically changed the capital structure. In February 2025, the company issued 114,754,700 common shares to Pax Rescue Vehicle, LLC for $10,000 plus legal fees, giving PRV over 90% of voting power and effecting a change in control as part of a going-private strategy. The company then declared DTC‑held common shares null and void, directed its transfer agent to cancel those shares, and filed a Form 15 to terminate Exchange Act registration.